Cas:127103-11-1 goralatide manufacturer & supplier

Chemical Name:goralatide

CAS.NO:127103-11-1

Synonyms:goralatide;L-Proline, N-acetyl-L-seryl-L-α-aspartyl-L-lysyl-;Acetyl-Ser-Asp-Lys-Pro;NAcSerDAspLysPro;N-Acetyl-L-seryl-L-α-aspartyl-L-lysyl-L-proline;MFCD00133611;1-(N2-(N-(N-Acetyl-L-seryl)-L-a-aspartyl)-L-lysyl)-L-proline;Ac-Ser-Asp-Lys-Pro-OH;Thymosin β4 (1-4);N-Acetyl-Ser-Asp-Lys-Pro

Molecular Formula:C₂₀H₃₃N₅O₉

Molecular Weight:487.504

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:992.0±65.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.565

PSA:238.93000

Exact Mass:487.227814

LogP:-1.91

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like goralatide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-Acetyl-Ser-Asp-Lys-Pro physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00133611 Use and application,Thymosin β4 (1-4) technical grade,usp/ep/jp grade.

Related News: Singapore, Australia, New Zealand, and the United States have banned all foreign nationals traveling from China from entering the country. goralatide manufacturer The company��s iPSC product platform unites stem cell biology and precision genetic engineering to create renewable master engineered iPSC lines that can be repeatedly used to mass produce cancer-fighting immune cells, replacing the high production costs, weeks of manufacturing time, and complex engineering processes required for current-generation CAR T-cell immunotherapies with an off-the-shelf product that has the potential to reach many more patients. goralatide supplier Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity. goralatide vendor Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease. goralatide factory Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease.